Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Marsha L. Crochiere, PhD, Stefan Hannus, PhD, Kerrin Hansen, Frank Becker, PhD, Erkan Baloglu, PhD, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 1563.

https://doi.org/10.1182/blood.V128.22.1563.1563

Published: 2016

Journal Articles

Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma

Christian Argueta, PhD, Hua Chang, PhD, Trinayan Kashyap, MS, Sivan Elloul, PhD, Sharon Friedlander, PhD, Margaret S. Lee, PhD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, William Senapedis, PhD, Erkan Baloglu, PhD MBA

Blood (2016) 128 (22): 3298.

https://doi.org/10.1182/blood.V128.22.3298.3298

Published: 2016

Journal Articles

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Yan Cui, MD, Joel G Turner, PhD, Jana L Dawson, BS, Juan A Gomez, BS, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Erkan Baloglu, PhD, William S. Dalton, PhD MD, Taiga Nishihori, MD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 5662.

https://doi.org/10.1182/blood.V128.22.5662.5662

Published: 2016

Journal Articles

Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis

Dongqing Yan, PhD, Srinivas K. Tantravahi, MD, Anthony D. Pomicter, MS, Anna Senina, MS, Kevin C. Gantz, Hannah M. Redwine, Josef T. Prchal, MD, Sabina Swierczek, PhD, Phillip M. Clair, MS, Anna M. Eiring, PhD, Erkan Baloglu, PhD MBA, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2016) 128 (22): 636.

https://doi.org/10.1182/blood.V128.22.636.636

Published: 2016

Journal Articles

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

Melissa A. Fischer, PhD, Sharon Friedlander, PhD, Leah Hogdal, PhD, Pia Arrate, Hua Chang, PhD, Trinayan Kashyap, MS, Christian Argueta, PhD, Boris Klebanov, MA, MS, William Senapedis, PhD, Erkan Baloglu, PhD MBA, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael R. Savona, MD

Blood (2016) 128 (22): 3949.

https://doi.org/10.1182/blood.V128.22.3949.3949

Published: 2016

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Blood (2015) 126 (23): 317.

https://doi.org/10.1182/blood.V126.23.317.317

Published: 2015

Journal Articles

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Julia Etchin, PhD, Alla Berezovskaya, Amy Saur Conway, Weihsu Claire Chen, PhD, Erkan Baloglu, PhD, Yosef Landesman, PhD, William Senapedis, PhD, Joel Ellis, PhD, Dilara McCauley, PhD, Richard M. Stone, MD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Michael Kauffman, Sharon Shacham, Jean C.Y. Wang, MDPhD, A. Thomas Look, MD

Blood (2015) 126 (23): 326.

https://doi.org/10.1182/blood.V126.23.326.326

Published: 2015

Journal Articles

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Shaneice Mitchell, BS, Shelley Orwick, BS, Matthew Cannon, BS, Virginia M. Goettl, DVM , PhD, Taylor D. LaFollette, Erkan Baloglu, PhD, William Senapedis, PhD, Alison R. Walker, MD, Bhavana Bhatnagar, Alice S. Mims, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, David M. Lucas, PhD, James S. Blachly, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2471.

https://doi.org/10.1182/blood.V126.23.2471.2471

Published: 2015

Journal Articles

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Paul Brent Ferrell, Jr., MD, William Senapedis, PhD, Alexander Cook, Erkan Baloglu, PhD, Yosef Landesman, PhD, Jonathan Michael Irish, PhD, Michael R. Savona, MD

Blood (2015) 126 (23): 3686.

https://doi.org/10.1182/blood.V126.23.3686.3686

Published: 2015

Journal Articles

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

Mariateresa Fulciniti, PhD, Rajya Lakshmi Bandi, BS, Nicola Amodio, PhD, Antonia Cagnetta, MD, William Senapedis, PhD, Erkan Baloglu, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3381.

https://doi.org/10.1182/blood.V124.21.3381.3381

Published: 2014

Journal Articles

In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs

Marsha Crochiere, PhD, Boris Klebanov, M.A., MsC, Erkan Baloglu, PhD, Ori Kalid, PhD, Trinayan Kashyap, MSc, William Senapedis, PhD, Diego del Alamo, BS, Tami Rashal, MD, Sharon Tamir, PhD, Dilara McCauley, PhD, Robert Carlson, PhD, Michael Savona, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhDMBA, Yosef Landesman, PhD

Blood (2014) 124 (21): 5196.

https://doi.org/10.1182/blood.V124.21.5196.5196

Published: 2014

Journal Articles

Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies

William Senapedis, PhD, Ryan George, PhD, Dilara McCauley, PhD, Joel Ellis, PhD, Marsha Crochiere, PhD, Michael Savona, MD, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Erkan Baloglu, PhD

Blood (2014) 124 (21): 2208.

https://doi.org/10.1182/blood.V124.21.2208.2208

Published: 2014

NARROW

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs

Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only